Distributor inventory | Tablet
Entecavir 0.5 mg
Treatment of chronic hepatitis B virus (HBV) infection in adults (and eligible adolescents/children as prescribed), including patients with compensated liver disease; may also be used in lamivudine-resistant HBV as per specialist advice.
Entecavir is a nucleoside analogue antiviral that inhibits hepatitis B virus DNA polymerase (reverse transcriptase). It blocks viral DNA replication, reducing HBV viral load and liver inflammation over time.
Oral tablet. Take exactly as prescribed, usually once daily. Take on an empty stomach (at least 2 hours after food and at least 2 hours before the next meal). Do not stop abruptly without medical advice.
Common side effects of ENTAVIR 0.5MG TAB may include:
Not a cure for HBV; long-term therapy may be required. Stopping entecavir can cause severe acute exacerbation of hepatitis—liver function should be monitored for several months after discontinuation. Risk of lactic acidosis and severe hepatomegaly with steatosis (rare) especially in advanced liver disease; seek care for unusual weakness, muscle pain, breathing trouble, abdominal pain, or sudden worsening. Use cautiously in renal impairment; dose adjustment may be needed. HIV/HBV co-infection: do not use without effective antiretroviral therapy due to risk of HIV resistance. Not recommended for self-medication.
